JP7860003B2 - キナゾリン化合物、その製造方法および用途 - Google Patents
キナゾリン化合物、その製造方法および用途Info
- Publication number
- JP7860003B2 JP7860003B2 JP2022580317A JP2022580317A JP7860003B2 JP 7860003 B2 JP7860003 B2 JP 7860003B2 JP 2022580317 A JP2022580317 A JP 2022580317A JP 2022580317 A JP2022580317 A JP 2022580317A JP 7860003 B2 JP7860003 B2 JP 7860003B2
- Authority
- JP
- Japan
- Prior art keywords
- group
- mmol
- substituted
- iii
- mixture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2020099104 | 2020-06-30 | ||
| CNPCT/CN2020/099104 | 2020-06-30 | ||
| CNPCT/CN2021/075828 | 2021-02-07 | ||
| CN2021075828 | 2021-02-07 | ||
| PCT/CN2021/103372 WO2022002102A1 (en) | 2020-06-30 | 2021-06-30 | Quinazoline compounds, preparation methods and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023531269A JP2023531269A (ja) | 2023-07-21 |
| JP2023531269A5 JP2023531269A5 (cg-RX-API-DMAC7.html) | 2024-06-24 |
| JP7860003B2 true JP7860003B2 (ja) | 2026-05-15 |
Family
ID=79317503
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022580317A Active JP7860003B2 (ja) | 2020-06-30 | 2021-06-30 | キナゾリン化合物、その製造方法および用途 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20230242544A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4175947A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7860003B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN115836055A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022002102A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (121)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019217307A1 (en) | 2018-05-07 | 2019-11-14 | Mirati Therapeutics, Inc. | Kras g12c inhibitors |
| AU2019338207B2 (en) | 2018-09-10 | 2025-01-02 | Mirati Therapeutics, Inc. | Combination therapies |
| SMT202500028T1 (it) | 2018-09-10 | 2025-03-12 | Mirati Therapeutics Inc | Terapie combinate |
| CA3112043A1 (en) | 2018-09-10 | 2020-03-19 | Mirati Therapeutics, Inc. | Combination therapies |
| US12208099B2 (en) | 2018-09-10 | 2025-01-28 | Mirati Therapeutics, Inc. | Combination therapies |
| US12377101B2 (en) | 2018-12-05 | 2025-08-05 | Mirati Therapeutics, Inc. | Combination therapies |
| WO2020146613A1 (en) | 2019-01-10 | 2020-07-16 | Mirati Therapeutics, Inc. | Kras g12c inhibitors |
| CN114615981B (zh) | 2019-08-29 | 2024-04-12 | 米拉蒂治疗股份有限公司 | Kras g12d抑制剂 |
| CN114761012B (zh) | 2019-09-24 | 2025-03-21 | 米拉蒂治疗股份有限公司 | 组合疗法 |
| WO2021085653A1 (en) | 2019-10-31 | 2021-05-06 | Taiho Pharmaceutical Co., Ltd. | 4-aminobut-2-enamide derivatives and salts thereof |
| EP4067343A4 (en) | 2019-11-29 | 2024-01-03 | Taiho Pharmaceutical Co., Ltd. | NEW PHENOLIC COMPOUND OR SALT THEREOF |
| PH12022551513A1 (en) | 2019-12-20 | 2023-04-24 | Mirati Therapeutics Inc | Sos1 inhibitors |
| WO2021215544A1 (en) | 2020-04-24 | 2021-10-28 | Taiho Pharmaceutical Co., Ltd. | Kras g12d protein inhibitors |
| US12702658B2 (en) | 2020-04-24 | 2026-08-11 | Taiho Pharmaceutical Co., Ltd. | Anticancer combination therapy with N-(1-acryloyl-azetidin-3-yl)-2-((1H-indazol-3-yl)amino)methyl)-1H-imidazole-5-carboxamide inhibitor of KRAS-G12C |
| US12655160B2 (en) | 2020-08-04 | 2026-06-16 | Mirati Therapeutics, Inc. | KRAS G12D inhibitors |
| TWI829003B (zh) * | 2020-08-12 | 2024-01-11 | 美商建南德克公司 | 喹唑啉化合物之合成 |
| EP4210833A4 (en) | 2020-09-11 | 2024-09-11 | Mirati Therapeutics, Inc. | CRYSTALLINE FORMS OF A KRAS G12C INHIBITOR |
| EP4216951B1 (en) | 2020-09-22 | 2026-04-01 | Mirati Therapeutics, Inc. | Kras g12d inhibitors |
| CN116323624B (zh) * | 2020-09-30 | 2026-07-10 | 上海医药集团股份有限公司 | 一种喹唑啉类化合物及其应用 |
| WO2022105859A1 (en) * | 2020-11-20 | 2022-05-27 | Jacobio Pharmaceuticals Co., Ltd. | Kras g12d inhibitors |
| WO2022109487A1 (en) | 2020-11-23 | 2022-05-27 | Merck Sharp & Dohme Corp. | Spirocyclic-substituted 6,7-dihydro-pyrano[2,3-d]pyrimidine inhibitors of kras g12c mutant |
| EP4262807A4 (en) | 2020-12-15 | 2025-04-23 | Mirati Therapeutics, Inc. | Azachinazoline pan-KRAS inhibitors |
| WO2022133038A1 (en) | 2020-12-16 | 2022-06-23 | Mirati Therapeutics, Inc. | Tetrahydropyridopyrimidine pan-kras inhibitors |
| JP2024505594A (ja) * | 2021-02-09 | 2024-02-06 | メッドシャイン ディスカバリー インコーポレイテッド | ピリミジン芳香環化合物 |
| MX2023008463A (es) * | 2021-02-16 | 2023-12-07 | Leidos Biomedical Res Inc | Composiciones y métodos para la inhibición del gen del virus de sarcoma de rata kirsten (kras). |
| KR20230169967A (ko) * | 2021-03-12 | 2023-12-18 | 브리스톨-마이어스 스큅 컴퍼니 | Kras g12d 억제제 |
| CN115260214A (zh) * | 2021-04-29 | 2022-11-01 | 药雅科技(上海)有限公司 | 稠环类krasg12d突变蛋白抑制剂的制备及其应用 |
| CN115160309B (zh) * | 2021-04-07 | 2024-04-09 | 药雅科技(上海)有限公司 | Krasg12c突变蛋白杂环类抑制剂的制备及其应用 |
| CN115141215B (zh) * | 2021-03-30 | 2023-09-15 | 上海德琪医药科技有限公司 | Kras g12d蛋白抑制剂和其用途 |
| CN117715915A (zh) * | 2021-04-09 | 2024-03-15 | 杭州英创医药科技有限公司 | 作为kras g12d抑制剂的杂环化合物 |
| WO2022221386A1 (en) * | 2021-04-14 | 2022-10-20 | Erasca, Inc. | Selective kras inhibitors |
| US20240239788A1 (en) * | 2021-04-16 | 2024-07-18 | Merck Sharp & Dohme Llc | Small molecule inhibitors of kras g12d mutant |
| WO2022232331A1 (en) * | 2021-04-29 | 2022-11-03 | Amgen Inc. | Heterocyclic compounds and methods of use |
| EP4329888A1 (en) * | 2021-04-29 | 2024-03-06 | Amgen Inc. | 2-aminobenzothiazole compounds and methods of use thereof |
| EP4332105A4 (en) * | 2021-04-30 | 2025-05-28 | Genfleet Therapeutics (Shanghai) Inc. | PYRIDINO- OR PYRIMIDO-CYCLIC COMPOUND, ITS PREPARATION PROCESS AND ITS MEDICAL USE |
| IL308195A (en) | 2021-05-05 | 2024-01-01 | Revolution Medicines Inc | RAS inhibitors for cancer treatment |
| WO2022235866A1 (en) | 2021-05-05 | 2022-11-10 | Revolution Medicines, Inc. | Covalent ras inhibitors and uses thereof |
| PE20240088A1 (es) | 2021-05-05 | 2024-01-16 | Revolution Medicines Inc | Inhibidores de ras |
| CN115385938A (zh) * | 2021-05-25 | 2022-11-25 | 江苏恒瑞医药股份有限公司 | 苯并嘧啶类化合物、其制备方法及其在医药上的应用 |
| CN117500799A (zh) * | 2021-06-09 | 2024-02-02 | 伊莱利利公司 | 作为kras g12d抑制剂的取代的稠合吖嗪 |
| WO2022258974A1 (en) * | 2021-06-10 | 2022-12-15 | Redx Pharma Plc | Quinazoline derivatives useful as ras inhibitiors |
| CN115466272A (zh) * | 2021-06-11 | 2022-12-13 | 博瑞生物医药(苏州)股份有限公司 | 一种嘧啶并杂环化合物,包含其的药物组合物及其用途 |
| WO2022262686A1 (en) * | 2021-06-13 | 2022-12-22 | Jingrui Biopharma Co., Ltd. | Kras g12d inhibitors |
| WO2022266206A1 (en) | 2021-06-16 | 2022-12-22 | Erasca, Inc. | Kras inhibitor conjugates |
| CA3221811A1 (en) * | 2021-06-30 | 2023-01-05 | Dana-Farber Cancer Institute, Inc. | Small molecule inhibitors of kras g12d mutant |
| CA3227138A1 (en) | 2021-07-23 | 2023-01-26 | Theras, Inc. | Compositions and methods for inhibition of ras |
| EP4378478A4 (en) | 2021-07-27 | 2025-11-12 | Toray Industries | MEDICINE FOR THE TREATMENT AND/OR PREVENTION OF CANCER |
| WO2023039240A1 (en) * | 2021-09-13 | 2023-03-16 | Biomea Fusion, Inc. | IRREVERSIBLE INHIBITORS OF KRas |
| WO2023061294A1 (zh) * | 2021-10-13 | 2023-04-20 | 再鼎医药(上海)有限公司 | 含氮杂环类衍生物调节剂、其制备方法及应用 |
| EP4417606A4 (en) * | 2021-10-15 | 2025-10-22 | Sunshine Lake Pharma Co Ltd | NOVEL PYRIMIDOPYRIDINE COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF |
| WO2023072188A1 (zh) * | 2021-10-29 | 2023-05-04 | 贝达药业股份有限公司 | Kras g12d抑制剂及其在医药上的应用 |
| WO2023103523A1 (zh) * | 2021-12-09 | 2023-06-15 | 苏州浦合医药科技有限公司 | 取代的双环杂芳基化合物作为kras g12d抑制剂 |
| WO2023138583A1 (zh) * | 2022-01-21 | 2023-07-27 | 上海湃隆生物科技有限公司 | 杂环类化合物、药物组合物及其应用 |
| JP7629580B1 (ja) * | 2022-01-21 | 2025-02-13 | ユーシノヴァ・ファーマシューティカルズ・リミテッド | ベンゾピリミジン化合物及びその使用 |
| IL314486A (en) * | 2022-02-03 | 2024-09-01 | Mirati Therapeutics Inc | Quinazoline compounds inhibit PAN-KRAS |
| CA3243798A1 (en) | 2022-02-09 | 2023-08-17 | Quanta Therapeutics, Inc. | Kras Modulators and Their Uses |
| WO2023151621A1 (zh) * | 2022-02-11 | 2023-08-17 | 泰励生物科技(上海)有限公司 | 具有抗kras突变肿瘤活性的化合物 |
| CN118715215A (zh) * | 2022-02-16 | 2024-09-27 | 美国安进公司 | 作为突变kras蛋白抑制剂的喹唑啉化合物及其用途 |
| WO2023172940A1 (en) | 2022-03-08 | 2023-09-14 | Revolution Medicines, Inc. | Methods for treating immune refractory lung cancer |
| JP2025510656A (ja) * | 2022-03-24 | 2025-04-15 | ベイジーン スウィッツァーランド ゲーエムベーハー | 複素環式化合物、その組成物、及びそれらを用いた治療方法 |
| CN114573438A (zh) * | 2022-03-31 | 2022-06-03 | 上海应用技术大学 | 一种单氟氯/溴代丙酮类化合物及其制备方法 |
| CN116891488B (zh) * | 2022-04-11 | 2025-12-12 | 成都海博为药业有限公司 | 稠环化合物、包含其的药物组合物及应用 |
| AU2023265688A1 (en) | 2022-05-06 | 2024-10-17 | PAQ Therapeutics Inc. | Kras g12d proteolysis targeting chimeras |
| WO2023230190A1 (en) | 2022-05-25 | 2023-11-30 | Quanta Therapeutics, Inc. | Pyrimidine based modulators and uses thereof |
| EP4536364A1 (en) | 2022-06-10 | 2025-04-16 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| TW202400600A (zh) * | 2022-06-16 | 2024-01-01 | 美商昂勝醫療科技股份有限公司 | 喹唑啉衍生物、其組成物及方法 |
| WO2024008068A1 (en) * | 2022-07-04 | 2024-01-11 | Jacobio Pharmaceuticals Co., Ltd. | K-ras mutant protein inhibitors |
| WO2024019103A1 (ja) | 2022-07-21 | 2024-01-25 | アステラス製薬株式会社 | G12d変異krasタンパクに作用する複素環化合物 |
| CN120019052A (zh) * | 2022-08-05 | 2025-05-16 | 瑟拉斯有限公司 | 用于抑制kras的组合物和方法 |
| US20260035376A1 (en) * | 2022-08-05 | 2026-02-05 | Theras, Inc. | Compositions and methods for inhibition of ras |
| JPWO2024034591A1 (cg-RX-API-DMAC7.html) | 2022-08-09 | 2024-02-15 | ||
| KR20250048078A (ko) | 2022-08-11 | 2025-04-07 | 브리스톨-마이어스 스큅 컴퍼니 | Kras 억제제 |
| AU2023322690A1 (en) * | 2022-08-12 | 2025-03-20 | Astellas Pharma Inc. | Anti cancer combinations comprising chemotherapy |
| EP4568674A1 (en) | 2022-08-12 | 2025-06-18 | Astellas Pharma Inc. | Combination of anticancer agents comprising a bifunctional compound with g12d mutant kras inhibitory activity |
| WO2024061333A1 (zh) * | 2022-09-21 | 2024-03-28 | 甘李药业股份有限公司 | 一种kras突变蛋白抑制剂、及其制备方法和应用 |
| KR20250075709A (ko) * | 2022-09-30 | 2025-05-28 | 트라스베다 리미티드 | 항-kras 돌연변이 종양 활성을 갖는 화합물 |
| CN117886833A (zh) * | 2022-10-13 | 2024-04-16 | 广东东阳光药业股份有限公司 | 一种嘧啶并吡啶化合物、其药物组合物及其用途 |
| CN117263959A (zh) * | 2022-10-24 | 2023-12-22 | 药雅科技(上海)有限公司 | 芳香类kras突变蛋白抑制剂的制备及其应用 |
| AU2023377064A1 (en) | 2022-11-09 | 2025-05-22 | Revolution Medicines, Inc. | Compounds, complexes, and methods for their preparation and of their use |
| CN116554208A (zh) * | 2022-12-02 | 2023-08-08 | 苏州浦合医药科技有限公司 | 取代的双环杂芳基化合物作为kras g12d抑制剂 |
| WO2024158242A1 (ko) * | 2023-01-25 | 2024-08-02 | 주식회사 엔바이오스 | Kras g12d 돌연변이 억제용 화합물 및 이를 유효성분으로 포함하는 암질환 예방 또는 치료용 조성물 |
| EP4680609A1 (en) | 2023-03-15 | 2026-01-21 | Quanta Therapeutics, Inc. | Kras modulators and uses thereof |
| CN121487738A (zh) | 2023-03-30 | 2026-02-06 | 锐新医药公司 | 诱导ras gtp水解的组合物和其用途 |
| WO2024211712A1 (en) | 2023-04-07 | 2024-10-10 | Revolution Medicines, Inc. | Condensed macrocyclic compounds as ras inhibitors |
| CN121487951A (zh) | 2023-04-07 | 2026-02-06 | 锐新医药公司 | 大环ras抑制剂 |
| AU2024251341A1 (en) | 2023-04-14 | 2025-10-16 | Revolution Medicines, Inc. | Crystalline forms of a ras inhibitor |
| EP4695261A1 (en) | 2023-04-14 | 2026-02-18 | Revolution Medicines, Inc. | Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof |
| KR20260019479A (ko) | 2023-05-04 | 2026-02-10 | 레볼루션 메디슨즈, 인크. | Ras 관련 질환 또는 장애를 위한 병용 요법 |
| AR133027A1 (es) | 2023-06-22 | 2025-08-20 | Astellas Pharma Inc | Composición farmacéutica que comprende un compuesto de quinazolina |
| JP2026523985A (ja) * | 2023-06-28 | 2026-07-16 | サンシャイン・レイク・ファーマ・カンパニー・リミテッド | ピリミドピリジン化合物、その医薬組成物及びその使用 |
| CN121889155A (zh) | 2023-08-07 | 2026-04-17 | 锐新医药公司 | 用于治疗ras蛋白相关疾病或病症的rmc-6291 |
| AU2024337016A1 (en) * | 2023-09-08 | 2026-04-16 | Tyligand Bioscience (Shanghai) Limited | Ras inhibitor |
| KR20260087586A (ko) | 2023-10-03 | 2026-06-11 | 피에이큐 테라퓨틱스 인코포레이티드 | Kras 단백질분해 표적화 키메라 |
| TW202523324A (zh) * | 2023-10-08 | 2025-06-16 | 大陸商成都海博為藥業有限公司 | 一種稠環化合物及應用 |
| US20250114346A1 (en) | 2023-10-09 | 2025-04-10 | Incyte Corporation | Combination therapy using a kras g12d inhibitor and pd-1 inhibitor or pd-l1 inhibitor |
| KR20260110993A (ko) | 2023-10-09 | 2026-07-14 | 인사이트 코포레이션 | Kras g12d 억제제 및 egfr 억제제를 포함하는 암 치료용 조합 |
| KR20260084633A (ko) * | 2023-10-10 | 2026-06-05 | 청두 하이퍼웨이 파마슈티컬스 컴퍼니 리미티드 | 축합 고리 화합물 및 kras 억제제로서의 응용 |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025085580A1 (en) * | 2023-10-17 | 2025-04-24 | Windermere Therapeutics, Inc. | Kras(g12d) inhibitors |
| KR20260096846A (ko) | 2023-10-20 | 2026-06-24 | 머크 샤프 앤드 돔 엘엘씨 | Kras 단백질의 소분자 억제제 |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
| WO2026090116A2 (en) | 2024-10-21 | 2026-04-30 | Revolution Medicines, Inc. | Ras inhibitors |
| US20260108528A1 (en) | 2024-10-22 | 2026-04-23 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2026090245A1 (en) | 2024-10-22 | 2026-04-30 | Revolution Medicines, Inc. | Use of ras inhibitors for treating cancer |
| WO2026090333A1 (en) | 2024-10-23 | 2026-04-30 | Incyte Corporation | Combination using a kras g12d inhibitor and chemotherapy combinations as well as their use in the treatment of cancer |
| US20260137674A1 (en) | 2024-10-23 | 2026-05-21 | Incyte Corporation | Combination therapy using a kras g12d inhibitor, and a nucleoside analog, and/or a microtubule inhibitor |
| WO2026106912A1 (en) | 2024-11-12 | 2026-05-21 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026112260A1 (en) | 2024-11-21 | 2026-05-28 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026122764A2 (en) | 2024-12-06 | 2026-06-11 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026128688A2 (en) | 2024-12-13 | 2026-06-18 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026161839A1 (en) | 2025-01-27 | 2026-07-30 | Revolution Medicines, Inc. | Ras inhibitors |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017172979A1 (en) | 2016-03-30 | 2017-10-05 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use |
| WO2021107160A1 (en) | 2019-11-29 | 2021-06-03 | Taiho Pharmaceutical Co., Ltd. | A compound having inhibitory activity against kras g12d mutation |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX380928B (es) * | 2013-10-10 | 2025-03-12 | Araxes Pharma Llc | Inhibidores de kras g12c. |
| US10011600B2 (en) * | 2014-09-25 | 2018-07-03 | Araxes Pharma Llc | Methods and compositions for inhibition of Ras |
| KR102932353B1 (ko) * | 2015-11-16 | 2026-02-27 | 아락세스 파마 엘엘씨 | 치환된 헤테로사이클릭 그룹을 포함하는 2-치환된 퀴나졸린 화합물 및 이의 사용 방법 |
| CN110869358A (zh) * | 2017-05-25 | 2020-03-06 | 亚瑞克西斯制药公司 | Kras的共价抑制剂 |
| CN114222743A (zh) * | 2019-08-16 | 2022-03-22 | 劲方医药科技(上海)有限公司 | 氧代六元环并嘧啶类化合物,其制法与医药上的用途 |
| WO2022061251A1 (en) * | 2020-09-18 | 2022-03-24 | Plexxikon Inc. | Compounds and methods for kras modulation and indications therefor |
| CN116323624B (zh) * | 2020-09-30 | 2026-07-10 | 上海医药集团股份有限公司 | 一种喹唑啉类化合物及其应用 |
| US20240034733A1 (en) * | 2020-11-03 | 2024-02-01 | Mirati Therapeutics, Inc. | Kras g12d inhibitors |
| WO2022105859A1 (en) * | 2020-11-20 | 2022-05-27 | Jacobio Pharmaceuticals Co., Ltd. | Kras g12d inhibitors |
-
2021
- 2021-06-30 WO PCT/CN2021/103372 patent/WO2022002102A1/en not_active Ceased
- 2021-06-30 CN CN202180046601.4A patent/CN115836055A/zh active Pending
- 2021-06-30 EP EP21833587.5A patent/EP4175947A4/en active Pending
- 2021-06-30 US US18/011,138 patent/US20230242544A1/en active Pending
- 2021-06-30 JP JP2022580317A patent/JP7860003B2/ja active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017172979A1 (en) | 2016-03-30 | 2017-10-05 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use |
| WO2021107160A1 (en) | 2019-11-29 | 2021-06-03 | Taiho Pharmaceutical Co., Ltd. | A compound having inhibitory activity against kras g12d mutation |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022002102A1 (en) | 2022-01-06 |
| EP4175947A4 (en) | 2024-07-03 |
| EP4175947A1 (en) | 2023-05-10 |
| CN115836055A (zh) | 2023-03-21 |
| JP2023531269A (ja) | 2023-07-21 |
| US20230242544A1 (en) | 2023-08-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023531269A (ja) | キナゾリン化合物、その製造方法および用途 | |
| JP7837952B2 (ja) | ヘテロアリール基化合物、その製造方法および使用 | |
| CN113748114B (zh) | 一种喹唑啉化合物及其在医药上的应用 | |
| KR102944305B1 (ko) | 헤테로 고리 화합물, 이의 제조 방법 및 용도 | |
| CN117586280A (zh) | Kras g12d抑制剂及其在医药上的应用 | |
| TW202144339A (zh) | 稠環化合物、其製備方法、藥物組合物及其應用 | |
| CN117624190A (zh) | Kras g12d抑制剂及其在医药上的应用 | |
| CA3255513A1 (en) | HETEROCYCLIC COMPOUND TO INDUCE DETERIORATION OF G12D MUTATION KRAS PROTEIN | |
| RU2666349C2 (ru) | Новое конденсированное пиримидиновое соединение или его соль | |
| WO2025053850A1 (en) | Covalent kras-binding compounds for medical treatment | |
| CN116143806A (zh) | 一类含氮杂环类化合物、制备方法和用途 | |
| CN115611923A (zh) | Kras g12d抑制剂及其在医药上的应用 | |
| KR20260068103A (ko) | Ras 억제제 | |
| CN118994158A (zh) | 一类含氮杂环类化合物、制备方法和用途 | |
| KR101797046B1 (ko) | 중수소화된 페닐 아미노 피리미딘 화합물 및 이 화합물을 함유하는 약물 조성물 | |
| JP6951406B2 (ja) | フラバグリン誘導体 | |
| JP2024532845A (ja) | ピリダジノンまたはピリジノン化合物、その製造方法および用途 | |
| CA2864672C (en) | Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme | |
| JP2022545326A (ja) | 複素環化合物、その製造方法及びその使用方法 | |
| AU2019372121A1 (en) | Heterocyclic compounds as BET inhibitors | |
| TW202122382A (zh) | 乙內醯脲衍生物 | |
| CN111683662A (zh) | 取代嘧啶类化合物及其药物组合物和治疗方法 | |
| CN113045559A (zh) | 一种二芳基脲类PI3Kα/mTOR双靶点抑制剂及其药物组合物和应用 | |
| CN120590414A (zh) | 一类含氮杂环类化合物、制备方法和用途 | |
| WO2021052501A1 (zh) | 杂环酰胺类化合物、其可药用的盐及其制备方法和用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20221226 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240614 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20240614 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20250522 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20250523 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250820 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20251028 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260218 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20260218 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20260403 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260403 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20260410 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20260430 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7860003 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |